PQF and LabCorp Build On Established Collaboration that Promotes
Appropriate Use of Innovative Technologies in Clinical Care
Company Website:
http://www.labcorp.com
BURLINGTON, N.C. -- (Business Wire)
Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH) announced today an expansion of its long-standing partnership
with the Perinatal Quality Foundation (PQF) to collaborate on a new
strategic initiative focused on noninvasive prenatal screening, the
Genetic Education Module (GEM).
PQF’s GEM initiative will provide education to help patients and
healthcare providers better understand the benefits and limitations of
noninvasive prenatal screening and how to interpret the results of that
screening. GEM will also build a patient registry designed to correlate
the results of noninvasive prenatal testing with the results of
confirmatory diagnostic tests, such as chorionic villus sampling (CVS)
or amniocentesis, as well as post-partum outcomes. In addition, the
initiative will help develop processes for credentialing healthcare
personnel in the delivery of pre- and post- screening information.
LabCorp and PQF are committed to improve patient outcomes and lives,
while lowering costs, through expanded access to emerging healthcare
technologies, such as their existing work on PQF’s Nuchal Translucency
Quality Review program, which provides education and credentialing for
sonographers and physicians involved in first trimester risk assessment.
"As new genetic technologies enter the market, it is imperative for
industry leaders, such as LabCorp, to foster the use of genetic
information and support the appropriate administration and
interpretation of these technologies,” said Dr. Ron Wapner and Dr. Larry
Platt, members of the PQF board of directors. “LabCorp is one of the
founding supporters of PQF, and we welcome LabCorp’s continued
assistance in helping PQF meet its objectives of educating patients and
providers."
“As a leader in integrated genetic testing and counseling services, we
are proud to support another important PQF objective, facilitating
physician and patient access to much-needed resources focused on
noninvasive prenatal screening," stated Dr. Marcia Eisenberg, LabCorp
Diagnostics’ Chief Scientific Officer. “Genetic testing is a rapidly
evolving area of medicine, and by working collaboratively with
organizations like PQF, we can advance access to, and understanding of,
high-quality test results for physicians and the patients they serve.”
LabCorp is a leader in women’s health and specialty genetics, and has
extensive experience developing and commercializing innovative maternal
diagnostic testing services, including noninvasive prenatal screening,
the SNP microarray and expanded carrier screening, that is changing the
way care is provided. LabCorp also offers integrated complementary
services to testing, such as clinical programs for maternal serum
screening, cytogenetics, single gene testing and the industry’s largest
team of genetic counselors, who support patients and their physicians
with analysis, assessment, and interpretation of genetic test results.
About LabCorp®
Laboratory Corporation of America® Holdings, an S&P 500
company, is the world’s leading healthcare diagnostics company,
providing comprehensive clinical laboratory services through LabCorp
Diagnostics, and end-to-end drug development support through Covance
Drug Development. LabCorp is a pioneer in commercializing new diagnostic
technologies and is improving people’s health by delivering the
combination of world-class diagnostics, drug development and knowledge
services. With combined revenue pro forma for the acquisition of Covance
in excess of $8.5 billion in 2014 and more than 48,000 employees in over
60 countries, LabCorp offers innovative solutions to healthcare
stakeholders. LabCorp clients include physicians, patients and
consumers, biopharmaceutical companies, government agencies, managed
care organizations, hospitals, and clinical labs. To learn more about
Covance Drug Development, visit www.covance.com.
To learn more about LabCorp and LabCorp Diagnostics, visit www.labcorp.com.
This press release contains forward-looking statements including with
respect to estimated 2015 guidance and the impact of various factors on
operating results. Each of the forward-looking statements is subject to
change based on various important factors, including without limitation,
competitive actions in the marketplace, adverse actions of governmental
and other third-party payers and the results from the Company’s
acquisition of Covance.Actual results could differ materially
from those suggested by these forward-looking statements. Further
information on potential factors that could affect LabCorp’s operating
and financial results is included in the Company’s Form 10-K for the
year ended December 31, 2014, and the Company’s Form 10-Q for the
quarter ended June 30, 2015, including in each case under the heading
risk factors, and in the Company’s other filings with the SEC, as well
as in the risk factors included in Covance’s filings with the SEC.The
information in this press release should be read in conjunction with a
review of the Company’s filings with the SEC including the information
in the Company’s Form 10-K for the year ended December 31, 2014, and
subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
About PQF
The Perinatal Quality Foundation was incorporated in Washington, D.C. in
2004 and in Oklahoma in 2010. It is an independent non-profit
foundation. The mission of the Perinatal Quality Foundation is to
improve the quality of Maternal-Fetal medicine medical services by
providing state of the art educational programs, and evidence-based,
statistically valid monitoring systems to evaluate current practices and
facilitate the transition of emerging technologies into clinical care.
The foundation is committed to disseminating safe and excellent
obstetrical practice protocols, and to providing clinician and provider
education, monitoring measures, and consensus discussions on emerging
obstetrical technologies. www.perinatalquality.org
View source version on businesswire.com: http://www.businesswire.com/news/home/20150903005217/en/
Contacts:
LabCorp®
Paul Surdez, 336-436-5076
Company
Information:www.labcorp.com
Source: Laboratory Corporation of America® Holdings
© 2024 Canjex Publishing Ltd. All rights reserved.